Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy.

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW.

Blood. 2019 May 10. pii: blood.2018885863. doi: 10.1182/blood.2018885863. [Epub ahead of print]

PMID:
31076448
2.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC.

J Clin Invest. 2019 Mar 21;130:2210-2221. doi: 10.1172/JCI126397.

3.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2019 Feb 21;4(4). pii: 127684. doi: 10.1172/jci.insight.127684. eCollection 2019 Feb 21. No abstract available.

4.

iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity.

Nobles CL, Reddy S, Salas-McKee J, Liu X, June CH, Melenhorst JJ, Davis MM, Zhao Y, Bushman FD.

Genome Biol. 2019 Jan 17;20(1):14. doi: 10.1186/s13059-019-1625-3.

5.

CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, DeGaramo DA, Levine BL, Fraietta JA.

Front Immunol. 2018 Dec 3;9:2740. doi: 10.3389/fimmu.2018.02740. eCollection 2018. Review.

6.

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.

Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, Amaravadi RK, Schuchter LM, Vonderheide RH.

Oncoimmunology. 2018 Aug 20;7(10):e1468956. doi: 10.1080/2162402X.2018.1468956. eCollection 2018.

7.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

8.

Neurotoxicity after CTL019 in a pediatric and young adult cohort.

Gofshteyn JS, Shaw PA, Teachey DT, Grupp SA, Maude S, Banwell B, Chen F, Lacey SF, Melenhorst JJ, Edmonson MJ, Panzer J, Barrett DM, McGuire JL.

Ann Neurol. 2018 Oct;84(4):537-546. doi: 10.1002/ana.25315. Epub 2018 Sep 26.

PMID:
30178481
9.

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Zhang C, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC.

Cancer Immunol Res. 2018 Sep;6(9):1100-1109. doi: 10.1158/2326-6066.CIR-17-0405. Epub 2018 Jul 20.

PMID:
30030295
10.

Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ.

Blood. 2018 Sep 6;132(10):1022-1026. doi: 10.1182/blood-2018-03-837609. Epub 2018 Jun 20.

PMID:
29925499
11.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.

Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ.

Nature. 2018 Jun;558(7709):307-312. doi: 10.1038/s41586-018-0178-z. Epub 2018 May 30.

12.

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH.

Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8.

PMID:
29807781
13.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ.

Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.

14.

Biomarkers in chimeric antigen receptor T-cell therapy.

Kong W, Lacey SF, Melenhorst JJ, Fraietta JA.

Biomark Med. 2018 May;12(5):415-418. doi: 10.2217/bmm-2018-0054. Epub 2018 Apr 26. No abstract available.

15.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. Erratum in: JCI Insight. 2019 Feb 21;4(4):.

16.

Toward precision manufacturing of immunogene T-cell therapies.

Xu J, Melenhorst JJ, Fraietta JA.

Cytotherapy. 2018 May;20(5):623-638. doi: 10.1016/j.jcyt.2017.12.007. Epub 2018 Apr 10. Review.

PMID:
29653875
17.

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.

Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20.

PMID:
29567081
18.

Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.

Lissina A, McLaren JE, Ilander M, Andersson EI, Lewis CS, Clement M, Herman A, Ladell K, Llewellyn-Lacey S, Miners KL, Gostick E, Melenhorst JJ, Barrett AJ, Price DA, Mustjoki S, Wooldridge L.

Sci Rep. 2018 Feb 7;8(1):2534. doi: 10.1038/s41598-017-18062-x.

19.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH.

JCI Insight. 2018 Jan 11;3(1). pii: 96976. doi: 10.1172/jci.insight.96976. eCollection 2018 Jan 11.

20.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.

N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.

21.

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, June CH.

Mol Ther. 2018 Jan 3;26(1):269-279. doi: 10.1016/j.ymthe.2017.10.012. Epub 2017 Oct 20.

22.

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey AD Jr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH.

Cancer Immunol Res. 2017 Dec;5(12):1152-1161. doi: 10.1158/2326-6066.CIR-17-0189. Epub 2017 Nov 6.

23.

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.

Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, Melenhorst JJ, Wasik MA.

Blood. 2017 Dec 7;130(23):2569-2572. doi: 10.1182/blood-2017-08-802413. Epub 2017 Oct 26. No abstract available.

24.

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF.

Blood. 2017 Nov 23;130(21):2317-2325. doi: 10.1182/blood-2017-06-786129. Epub 2017 Sep 21.

25.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19;9(399). pii: eaaa0984. doi: 10.1126/scitranslmed.aaa0984.

26.

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ.

Blood. 2017 Feb 23;129(8):1039-1041. doi: 10.1182/blood-2016-09-738245. Epub 2016 Dec 28. No abstract available.

27.

Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy.

Rubin CB, Elenitsas R, Taylor L, Lacey SF, Kulikovskaya I, Gupta M, Melenhorst JJ, Loren A, Frey N, June CH, Porter D, Rosenbach M.

J Am Acad Dermatol. 2016 Nov;75(5):1054-1057. doi: 10.1016/j.jaad.2016.06.062. No abstract available.

PMID:
27745631
28.

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S.

Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28. No abstract available.

PMID:
27677739
29.

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT.

Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.

30.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.

J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.

31.

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, Feldman MD, Porter DL, Grupp SA, June CH, Milone MC.

Blood. 2016 Jul 21;128(3):360-70. doi: 10.1182/blood-2016-01-694356. Epub 2016 May 10.

32.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA.

Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.

33.

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.

Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, Grupp SA, June CH, Melenhorst JJ, Lacey SF.

J Immunol Methods. 2016 Jul;434:1-8. doi: 10.1016/j.jim.2016.03.005. Epub 2016 Apr 3.

34.

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV.

Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.

35.

Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.

Dumitriu B, Ito S, Feng X, Stephens N, Yunce M, Kajigaya S, Melenhorst JJ, Rios O, Scheinberg P, Chinian F, Keyvanfar K, Battiwalla M, Wu CO, Maric I, Xi L, Raffeld M, Muranski P, Townsley DM, Young NS, Barrett AJ, Scheinberg P.

Lancet Haematol. 2016 Jan;3(1):e22-9. doi: 10.1016/S2352-3026(15)00227-6. Epub 2015 Dec 17.

36.

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A.

Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.

37.

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA.

N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.

38.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH.

Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.

39.

Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer.

Melenhorst JJ, Lacey SF, Bedoya F.

Curr Drug Targets. 2017;18(3):332-340. doi: 10.2174/1389450116666150825120427. Review.

PMID:
26302796
40.

CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.

Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM.

Sci Transl Med. 2015 Apr 29;7(285):285ra63. doi: 10.1126/scitranslmed.aaa2546. Erratum in: Sci Transl Med. 2016 Jan 13;8(321):321er1.

41.

Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.

Ito S, Barrett AJ, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, Larochelle A, Melenhorst JJ.

Stem Cell Res. 2015 Jan;14(1):95-104. doi: 10.1016/j.scr.2014.11.007. Epub 2014 Dec 6.

42.

Chimeric antigen receptor T cells for sustained remissions in leukemia.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA.

N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.

43.

Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM.

Mol Ther. 2015 Jan;23(1):179-83. doi: 10.1038/mt.2014.192. Epub 2014 Sep 30.

44.

Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, Chen J, Kotliarov Y, Cheung F, Xie Z, Marincola F, Tanimoto K, Battiwalla M, Olnes MJ, Perl S, Schum P, Hughes TE, Keyvanfar K, Hensel N, Muranski P, Young NS, Barrett AJ.

Mol Ther. 2014 Jul;22(7):1388-1395. doi: 10.1038/mt.2014.50. Epub 2014 Apr 1.

45.

Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.

Yin F, Battiwalla M, Ito S, Feng X, Chinian F, Melenhorst JJ, Koklanaris E, Sabatino M, Stroncek D, Samsel L, Klotz J, Hensel NF, Robey PG, Barrett AJ.

Stem Cells. 2014 May;32(5):1278-88. doi: 10.1002/stem.1638.

46.

Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.

Tanimoto K, Muranski P, Miner S, Fujiwara H, Kajigaya S, Keyvanfar K, Hensel N, Barrett AJ, Melenhorst JJ.

Cytotherapy. 2014 Jan;16(1):135-46. doi: 10.1016/j.jcyt.2013.08.008. Epub 2013 Oct 29.

PMID:
24176543
47.

Innovation and opportunity for chimeric antigen receptor targeted T cells.

Melenhorst JJ, Levine BL.

Cytotherapy. 2013 Sep;15(9):1046-53. doi: 10.1016/j.jcyt.2013.02.007. Epub 2013 Apr 2. Review.

PMID:
23562306
48.

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, Shpall EJ, Melenhorst JJ, Leen AM, Barrett AJ, Bollard CM.

Leukemia. 2013 Jul;27(7):1538-47. doi: 10.1038/leu.2013.66. Epub 2013 Mar 1.

49.

When one is better than two.

Melenhorst JJ.

Cytotherapy. 2013 Feb;15(2):139. doi: 10.1016/j.jcyt.2012.12.005. No abstract available.

PMID:
23321324
50.

Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant.

McIver Z, Melenhorst JJ, Wu C, Grim A, Ito S, Cho I, Hensel N, Battiwalla M, Barrett AJ.

Haematologica. 2013 Mar;98(3):346-52. doi: 10.3324/haematol.2012.072991. Epub 2012 Oct 12.

Supplemental Content

Loading ...
Support Center